Deciphering the genomic, epigenomic and transcriptomic landscapes of pre-invasive lung cancer lesions by Texeira, Vitor H. et al.
1 
 
Deciphering the genomic, epigenomic and transcriptomic landscapes of pre-invasive 1 
lung cancer lesions.  2 
 3 
Vitor H. Teixeira1*, Christodoulos P. Pipinikas1,2*, Adam Pennycuick1*, Henry Lee-Six3, 4 
Deepak Chandrasekharan1, Jennifer Beane4, Tiffany J. Morris2, Anna Karpathakis2, Andrew 5 
Feber2, Charles E. Breeze2, Paschalis Ntolios1, Robert E. Hynds1,5,6, Mary Falzon7, Arrigo 6 
Capitanio7, Bernadette Carroll8, Pascal F. Durrenberger9, Georgia Hardavella8, James M. 7 
Brown1, Andy G. Lynch10,11, Henry Farmery10, Dirk S. Paul2, Rachel C. Chambers9, Nicholas 8 
McGranahan5, Neal Navani1,8, Ricky M. Thakrar1,8, Charles Swanton5,6, Stephan Beck2, 9 
Phillip Jeremy George8, Avrum Spira4,12, Peter J. Campbell3, Christina Thirlwell2, Sam M. 10 
Janes1,8# 11 
 12 
1 Lungs for Living Research Centre, UCL Respiratory, University College London, London, 13 
U.K. 14 
2 Research Department of Cancer Biology and Medical Genomics Laboratory, UCL Cancer 15 
Institute, University College London, London, U.K. 16 
3 The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, U.K. 17 
4 Department of Medicine, Boston University School of Medicine, Boston, MA, U.S.A. 18 
5 CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, U.K.  19 
6 Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, U.K. 20 
7 Department of Pathology, University College London Hospitals NHS Trust, London, U.K. 21 
8 Department of Thoracic Medicine, University College London Hospital, London, U.K. 22 
9 Center for Inflammation and Tissue Repair, UCL Respiratory, University College London, 23 
London, U.K. 24 
10 Computational Biology and Statistics Laboratory, Cancer Research UK Cambridge 25 
Institute, Cambridge, U.K. 26 
11 School of Medicine/School of Mathematics and Statistics, University of St Andrews, St 27 
Andrews, U.K. 28 
2 
 
12 Johnson and Johnson Innovation, Cambridge MA 29 
 30 
* Drs. Teixeira, Pipinikas and Pennycuick contributed equally to this study. 31 
 32 
# Corresponding author:  33 
Professor Sam M. Janes  34 
Address: Lungs for Living Research Centre, UCL Respiratory, University College London, 5 35 
University Street, London, WC1E 6JF, U.K. 36 
Phone: (+44) 020 3549 5979  37 
E-mail: s.janes@ucl.ac.uk 38 
 39 
 40 
  41 
3 
 
Abstract 42 
  43 
 The molecular alterations that occur in cells before cancer is manifest are largely 44 
uncharted. Lung carcinoma-in-situ (CIS) lesions are the pre-invasive precursor to squamous 45 
cell carcinoma. While microscopically identical, their future is in equipoise with half 46 
progressing to invasive cancer and half regressing or remaining static. The cellular basis of 47 
this clinical observation is unknown. Here, we profile the genomic, transcriptomic and 48 
epigenomic landscape of CIS in a unique patient cohort with longitudinally monitored pre-49 
invasive disease. Predictive modelling identifies which lesions will progress with remarkable 50 
accuracy. We identify progression-specific methylation changes on a background of 51 
widespread heterogeneity, alongside a strong chromosomal instability signature. We 52 
observe mutations and copy number changes characteristic of cancer and chart their 53 
emergence, offering a window into early carcinogenesis. We anticipate this new 54 
understanding of cancer precursor biology will improve early detection, reduce over-55 
treatment and foster preventative therapies targeting early clonal events in lung cancer. 56 
 57 
 58 
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Introduction  63 
 64 
 Lung cancer is the commonest cause of cancer death worldwide with 1.5 million 65 
deaths per year1. Lung squamous cell carcinoma (LUSC) is the most common subtype in 66 
parts of Europe and second in the U.S.A.2 Before progression to invasive LUSC, there is 67 
step-wise evolution of ever more disordered pre-invasive lesions, ranging from mild and 68 
moderate dysplasia (low-grade lesions) to severe dysplasia and carcinoma-in-situ (CIS; 69 
high-grade lesions).3 The accessibility of the proximal airways allows detection and 70 
monitoring of these lesions using high-resolution diagnostic approaches such as 71 
autofluorescence bronchoscopy (AFB)4. This technique enables the acquisition of tissue 72 
throughout the natural history of LUSC, providing an excellent model to study early 73 
tumorigenesis in human patients. 74 
 Clinically, the optimal management of pre-invasive airway lesions remains unclear, 75 
despite the availability of surgery, radiotherapy and ablative techniques5. AFB with biopsy 76 
allows assessment of the size, gross morphology and histopathology of pre-invasive lesions 77 
(Fig. 1a, b) but cannot distinguish lesions that will ultimately progress to invasive tumours 78 
from those that will spontaneously regress. As such, indiscriminate surgical resection of pre-79 
invasive lesions or external beam radiotherapy probably represent over-treatment: lesions 80 
will spontaneously regress in 30% of cases, patient co-morbidity and poor lung function 81 
impart considerable risk, and the presence of field cancerization means independent lung 82 
cancers frequently emerge at sites outside resection or therapy margins.6 83 
 We reasoned that information on the future clinical trajectory of a pre-invasive lung 84 
lesion might be encoded in the genetic and epigenetic profile present at diagnosis. We 85 
therefore undertook a prospective cohort study of patients with pre-invasive squamous 86 
airway lesions. Patients were managed conservatively, undergoing surveillance AFB with 87 
biopsy and CT scanning every 4 and 12 months, respectively, with definitive cancer 88 
treatment only performed at the earliest pathological evidence of progression to invasive 89 
tumours (Fig. 1a, b).7 When a CIS lesion either progressed to invasive cancer or regressed 90 
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to normal epithelium/low-grade disease, molecular profiling was performed on the preceding 91 
CIS biopsy from the same lesion – the ‘index biopsy’ (Fig. 1c). Index biopsies all 92 
demonstrated histologically and morphologically indistinguishable CIS and were classified as 93 
either ‘progressive’ or ‘regressive’. All such index CIS biopsies were subjected to a 94 
predetermined combination of transcriptomic, epigenetic and finally genomic profiling 95 
depending on DNA/RNA availability (Fig. 1d; Table 1; Extended Data Fig. 1; 96 
Supplementary Table 1). 97 
 Whilst molecular techniques have revolutionized our understanding of cancer biology, 98 
the key steps from normal cell to the point of cancer (uncontrolled growth and invasion) 99 
remain unclear. This is, to our knowledge, a unique collection of high-grade pre-invasive 100 
lung lesions for which prospective follow-up under conservative management enabled their 101 
natural history to declare.  102 
 103 
Results 104 
 105 
Patient Characteristics 106 
 107 
Patients with pre-invasive lung cancer lesions were recruited through University College 108 
London Hospitals (UCLH) Early Lung Cancer Surveillance Programme (ELCSP). Full details 109 
of the surveillance protocol including eligibility criteria for patient inclusion have been 110 
previously described7. Briefly, the programme has recruited 140 patients to date with pre-111 
invasive lung cancer lesions of varying histological grades. 129 index CIS biopsies were 112 
obtained from 85 patients and subjected to molecular analysis (Supplementary Table 1). 113 
Dependent on stored tissue quantity, in total, 51 samples from 42 patients underwent gene 114 
expression profiling; 87 samples from 47 patients underwent methylation profiling; and 39 115 
samples from 29 patients underwent whole genome sequencing. Methylation and gene 116 
expression datasets were divided into independent discovery and validation groups. 117 
 Clinical characteristics within each analysis group are shown in Table 1. In comparing 118 
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progressive and regressive samples, we found that progressive samples were associated 119 
with a higher pack-year smoking history in the methylation discovery group only (p < 0.01) 120 
and with increased age in the WGS group (p = 0.01). No clinical differences were 121 
consistently observed across the different analysis groups.  122 
 123 
Characterization of CIS genomic profiles 124 
We believe that the 39 CIS lesions are the first pre-invasive LUSC lesions to be 125 
whole-genome sequenced, so we compared the burden and spectrum of mutations in CIS 126 
with publicly available LUSC exome sequencing data from The Cancer Genome Atlas 127 
(TCGA). Due to differences between whole-genome and exome sequencing, only broad 128 
comparisons can be made. We observe a similar mutation burden and copy number profile 129 
between CIS samples and TCGA LUSC tumours (Fig. 2). There is congruency of type and 130 
prevalence of potential driver mutations, broadly defined as any mutation in a gene 131 
previously implicated as a driver of lung cancer, between CIS and LUSC samples8. We 132 
observe frequent alterations in TP53, CDKN2A, SOX2 and AKT2, and less frequent 133 
alterations in FAT1, KMT2D, KEAP1, EGFR and NOTCH1 in CIS lesions (Fig. 2; 134 
Supplementary Table 2). CIS mutational signatures9,10 showed a strong tobacco-135 
associated signal and were similar to those found in LUSC (Extended Data Fig. 2). 136 
Marked aneuploidy was observed in CIS lesions, with somatic copy number 137 
alterations (CNAs) present across the genome (Fig. 2; Extended Data Fig. 3). The most 138 
frequent changes were associated with gain and amplification of multiple locations on distal 139 
3q: this is known to be the most common genomic aberration in LUSC11. Other recognised 140 
copy number associations identified in our data include gain/amplification in 5p, 8q and 19q 141 
and regions of loss/deletion in 3p, 4q, 5q, 8p, 9p and 13q.12-18 142 
Whilst most CIS samples have the genomic appearance of neoplasms, we observe 143 
six lesions which show markedly lower mutational load and fewer copy number alterations 144 
than the others (Extended Data Fig. 3; PD21884c, PD21885a, PD21885c, PD21904d, 145 
PD38317a, PD38319a). These samples have very few genomic changes, despite being CIS 146 
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histologically. All of these six samples regressed to normal epithelium or low-grade dysplasia 147 
on subsequent biopsy. Four further samples met this end-point for regression, despite 148 
widespread mutational and copy number changes. However, with longer follow up one of 149 
these cases developed CIS recurrence (Extended Data Fig. 4a; PD21893a), and two 150 
developed invasive cancer on further surveillance (Extended Data Fig. 4b,c; PD21884a, 151 
PD38326a). Only one sample, PD21908a, showed sustained clinical regression after 9 152 
years of follow up despite widespread molecular changes. 153 
All but one progressive sample and all highly mutated regressive samples showed 154 
amplification in a small region of distal 3q (chr3:172516434-178440382). This region 155 
contains the gene ECT2, a regulator of cytokinesis which is associated with chromosomal 156 
instability. Progressive sample PD38320a had little change outside this region and did not 157 
harbour a TP53 mutation, suggesting that this amplification may be a crucial early event in 158 
LUSC tumorigenesis. 159 
We compared genomic features between the 29 progressive and 10 regressive 160 
lesions. The three samples which showed evidence of progression after meeting our end-161 
point for regression were excluded from this analysis. Comparisons of mutation burden 162 
between progressive and regressive lesions were performed by mixed effects modelling, 163 
allowing us to account for samples that come from the same patient. Even after correcting 164 
for patient age, smoking history and sample purity, progressive lesions had more somatically 165 
acquired mutations than those from regressive lesions, across base substitutions (p<0.001), 166 
indels (p=0.018), structural variants (p<0.001) and copy number changes (p<0.001) 167 
(Extended Data Fig. 5a-d). When the analysis was restricted only to substitutions that were 168 
fully clonal in each lesion, there were still substantially more substitutions in progressive than 169 
regressive lesions (p<0.001) (Extended Data Fig. 5e), suggesting that the increase in 170 
mutation burden is not due to recent subclonal diversification in progressive lesions. All the 171 
mutational processes (or signatures9,10) identified in the CIS lesions contribute to the excess 172 
of mutations in progressive compared to regressive samples; however, only tobacco-173 
associated signature 4 showed proportionally more mutations (p=0.017) (Extended Data 174 
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Fig. 2f-j). Progressive lesions contained more putative driver mutations than regressive 175 
lesions (p=0.001) (Extended Data Fig. 5h; Supplementary Table 2). Importantly, no single 176 
cancer mutation perfectly discriminated between progressive and regressive lesions.  177 
Within the biopsied lesions, clonal architecture was similar between progressive and 178 
regressive lesions (Extended Data Fig. 5e-g). For four patients in whom we sequenced 179 
multiple progressive lesions, the lesions shared many somatic mutations despite their 180 
different locality in the bronchial tree, indicating their probable derivation from a common 181 
ancestral clone. By contrast, multiple regressive lesions from two further patients did not 182 
share common mutations and so are likely to have arisen independently (Extended Data 183 
Fig. 6). There were no differences in telomere lengths between progressive and regressive 184 
lesions (p=0.59) (Extended Data Fig. 5i). 185 
 186 
CIS transcriptomic and epigenetic profiles 187 
Gene expression microarrays were performed on a discovery set of 17 progressive 188 
and 16 regressive CIS lesions. We identified 1335 genes with significant expression 189 
changes (FDR < 0.01); 657 genes were up-regulated and 678 down-regulated in progressive 190 
CIS lesions (Fig. 3a and Supplementary Table 3). 191 
Differential analysis of methylation profiles was performed on a discovery set of 26 192 
progressive, 11 regressive and 23 control samples. Widespread methylation changes were 193 
observed with 12,064 differentially methylated positions (DMPs), associated with 2,695 194 
genes, at which methylation was significantly different between progressive and regressive 195 
samples (FDR < 0.01; |Δβ| > 0.3). 6,314 DMPs were hypermethylated and 5,750 196 
hypomethylated in progressive CIS (Fig. 3b and Supplementary Table 3). 260 differentially 197 
methylated regions (DMRs) were identified, of which 151 (58%) overlap with DMRs between 198 
TCGA cancer and control data (Extended Data Fig. 7). Finally, we identified 36,620 199 
differentially variable positions (DVPs) for which probe variance was markedly different 200 
between progressive and regressive groups.  201 
Of the 1335 genes identified, TPM3, PTPRB, SLC34A2, KEAP1, NKX2-1, SMAD4 202 
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and SMARCA4 have previously been implicated as potential lung cancer drivers 203 
(Supplementary Table 4). Regarding methylation, the potential driver genes NKX2-1, 204 
TERT, DDR2, LRIG3, CUX1, EPHA3, CSMD3, MET, ZNF479, GRIN2A, PTPRD, NOTCH1, 205 
CD74, NSD1 and CDKN2A contain at least one significant DMP. Several genes which are 206 
significant in our gene expression analysis are also identified in our methylation data, 207 
including multiple genes in the homeobox family (HOXC8, HOXC9, HOXC10, HOXD10, 208 
HOXA11AS), previously implicated as an early epigenetic event in multiple cancers19. NKX2-209 
1 (TTF-1) is the only putative driver gene to be identified in both gene expression and 210 
methylation analyses, and is also a member of the homeobox family. It is hypermethylated 211 
and underexpressed in progressive samples compared to regressive. This gene is widely 212 
used in diagnosis of lung adenocarcinoma and both underexpression and hypermethylation 213 
have been implicated in the development of this disease20,21. NKX2-1 loss has been shown 214 
to drive squamous cancer formation in combination with SOX2 overexpression22; focal gains 215 
in the 3q region containing SOX2 are commonly observed in progressive CIS (Extended 216 
Data Fig. 4). 217 
Principal component analysis of all gene expression and methylation data showed a 218 
clear distinction between the progressive and regressive subgroups (p=0.0017 and 219 
p=6.8x10-25, respectively) (Fig. 3c,d). In the methylation dataset, the regressive lesions 220 
closely clustered with the control normal epithelial cells. A history of chronic obstructive 221 
pulmonary disease (COPD) had an effect on case segregation (p=1.2x10-5) but all other 222 
clinical and technical variables analysed, including smoking status and history of lung 223 
cancer, had no effect (Extended Data Fig. 8a-f). This was also the case for PCA analysis of 224 
the gene expression data (Extended Data Fig. 8g-k). 225 
For methylation, one control and four regressive cases clustered with the progressive 226 
cases (Fig. 3d). Three of the four mis-classified regressive cases were subjected to whole-227 
genome sequencing and were found to have more copy number alterations than other 228 
regressive samples (PD21884a, PD21893a, PD21908a). Two of these correspond to the 229 
samples discussed above, which showed signs of progression after meeting the clinical end 230 
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point of regression (Extended Data Fig. 4). For the control bronchial epithelium sample that 231 
was classified with the progressive lesions, CIS was detected in a biopsy specimen 12 232 
months later from the same site. Thus, although we have formally treated these cases as 233 
mis-classifications, it is likely that the molecular data underpinning the apparent errors 234 
indicate a cellular phenotype that is not consistent with a straightforward regressive lesion. 235 
 236 
 237 
Molecular signatures predict CIS outcome  238 
The ability to predict if a pre-invasive lesion will progress to cancer has important 239 
clinical implications. For gene expression, we used the above pre-defined discovery set to 240 
define our classifier (n=33; 17 progressive, 16 regressive; 10-fold cross-validation applied). 241 
This was applied to a separate validation set (n=18; 10 progressive, 8 regressive). All 242 
samples in the validation set were classified correctly. When applied to external data from 243 
TCGA (n=551: 502 LUSC, 49 control), our 291-gene model was able to classify LUSC vs 244 
control samples with AUC=0.81 (Fig. 4a-c; Extended Data Fig. 9).  245 
An analogous analysis was performed for methylation using a discovery set of 60 246 
samples and a validation set of 27 samples. This classified validation samples with 247 
AUC=0.99 and classified external TCGA samples (n=412: 370 LUSC, 42 controls) into 248 
LUSC vs controls with AUC=0.99, based on a 141-DMP classifier (Extended Data Fig. 10a-249 
i).  250 
We observed an increased number of methylation probes with intermediate 251 
methylation in TCGA LUSC cancer vs TCGA control samples (Fig. 4d), reflecting 252 
methylation heterogeneity in these samples. We therefore developed a methylation 253 
heterogeneity index (MHI), defined as the number of probes per sample with tlo < ß < thi. 254 
Optimization based on our discovery set of 26 progressive and 11 regressive samples 255 
defined values of tlo = 0.26 and thi = 0.88. Control samples were not used in this analysis. 256 
This model classified progressive vs regressive CIS samples in our validation set with 257 
AUC=0.74 and TCGA LUSC vs TCGA control samples with AUC=0.96 (Fig. 4e; Extended 258 
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Data Fig. 10j-n). Multivariate logistic regression in our CIS cohort demonstrated that this 259 
index was a predictor of progression status (p=0.017); previous history of lung cancer was 260 
also significantly associated (p=0.02), whereas smoking status, COPD status, age and 261 
gender were not. 262 
Given the widespread nature of methylation changes, we hypothesised that this 263 
increase in heterogeneity may be a genome-wide process rather than specific to functional 264 
pathways. To test this theory, we assessed the predictive value of MHI calculated from a 265 
sample of 2,000 probes, randomly selected from across the genome. Running 10,000 266 
simulations with each using a different random sample of 2,000 probes gave a mean AUC 267 
for TCGA LUSC vs TCGA control of 0.95 (95% CI 0.92-0.98) (Fig. 4f), and for progressive 268 
vs regressive CIS of 0.75 (95% CI 0.69-0.82) (Extended Data Fig. 10n). These results are 269 
similar to those obtained using the entire set of 450,000 probes, suggesting that methylation 270 
heterogeneity is a genome-wide process. However, these AUC values are lower than those 271 
obtained from our predictive model based on just 141 differentially methylated positions, 272 
suggesting that specific methylation changes are also important, on this background of 273 
generalised change. 274 
To build a predictive classifier based on copy number, we used copy number derived 275 
from methylation data to increase sample size and classified 46 of 54 samples correctly 276 
(Extended Data Fig. 9g-i). The 154 predictive cytogenetic bands that we identified overlap 277 
with, but are not limited to, a model previously proposed by van Boerdonk et al.. Our model 278 
replicated their results, classifying 24/24 regressive samples and 9/12 progressive samples 279 
correctly23 (Extended Data Fig. 9j-l). When applied to external data from TCGA (n=763: 524 280 
LUSC, 239 control), our model was able to classify LUSC vs control samples with AUC=0.98 281 
(Extended Data Fig. 9m-o). 282 
 We performed further analyses using only one sample per patient to demonstrate that 283 
our results are not dependent on multiple sampling. The first available sample for each 284 
patient was selected, with CIS samples prioritized over control samples for methylation data. 285 
Results are similar to our analysis above, validating our initial results (data not shown). 286 
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 Although we cannot fully exclude that lesions meeting our end point for regression will 287 
progress in future, most patients in this cohort now have several years of follow up. Of 35 288 
regressive lesions undergoing molecular profiling (Supplementary Table 1), mean follow up 289 
was 67 months (median 57 months, range 11-150 months).  290 
 291 
CIN is an early marker of progression to cancer 292 
To investigate possible drivers of tumorigenic progression, we performed a 293 
differential analysis of gene expression data between the progressive and regressive 294 
groups. 5 of the top 100 genes identified have been previously associated with chromosomal 295 
instability (CIN)24, as defined by the previously published CIN70 signature25 (ACTL6A, 296 
ELAVL1, MAD2L1, NEK2, OIP5). All five are up-regulated in progressive compared with 297 
regressive samples. CIN-related genes can predict progression (Fig. 5a); NEK2 expression 298 
alone predicts progression with AUC=0.93 (Fig. 5b). 299 
Pathway analysis was performed using the gage Bioconductor package26 to compare 300 
our differentially expressed genes to KEGG gene sets. The CIN70 gene set was the most 301 
significant gene set identified (adjusted p value 8.9x10-32; up-regulated in progressive 302 
group), suggesting a role in early tumorigenesis. Cell cycle and DNA repair pathways were 303 
also implicated (Fig. 5c; Supplementary Table 5). Results were similar when cell-cycle 304 
associated genes were removed from the CIN70 signature, suggesting that this is a genuine 305 
CIN signal rather than a marker of proliferation. 306 
Performing similar differential analysis of differentially methylated probes found 307 
widespread changes. The top probes identified were associated with cancer-associated cell 308 
signalling pathways, including TGF-beta, WNT and Hedgehog, as well as cell cycle and CIN-309 
associated genes (Fig 5d).  310 
This CIN signal is consistent with the observed pattern of widespread copy number 311 
change (Fig. 2). Overall copy number variation for a sample, as measured by Weighted 312 
Genome Integrity Index (wGII)27, correlates with mean CIN-associated gene expression of 313 
that sample (Pearson r2=0.473) (Extended Data Fig. 5j). We also observe a correlation 314 
13 
 
between local copy number of a gene and expression of that gene, consistent with previous 315 
results28,29.  316 
 317 
 318 
 319 
 320 
Discussion 321 
In summary, we have delineated changes in the genomic architecture, genome-wide 322 
gene expression and DNA methylation of pre-invasive cancers with known histological 323 
evidence of subsequent disease progression or regression. The CIS genome shares many 324 
of the hallmarks of advanced, invasive LUSC but marked genomic, transcriptomic and 325 
epigenetic differences exist between lesions that are benign and those that will progress to 326 
cancer. Our data demonstrate the potential use of these differences in predicting outcome 327 
over current clinical practice.  328 
Among the strongest pathways associated with progression is chromosomal 329 
instability, defined as a high rate of gain or loss of whole (or parts of) chromosomes. CIN is 330 
implicated in many human cancers, including lung, and has been suggested both as a 331 
prognostic marker and therapeutic target30,31. Regressive lesions do not have the wholesale 332 
genomic instability of those that will progress and their epigenetic and transcriptional profiles 333 
more closely resemble normal bronchial epithelium than invasive cancers. Despite this, CIS 334 
lesions that spontaneously regress are genuine neoplasms; they harbour many somatic 335 
mutations, which can include known potential driver mutations. The mechanism of 336 
regression remains mysterious: it is unclear whether clones become exhausted and die out, 337 
potentially abetted by immune surveillance, or whether clones persist but phenotypically 338 
revert to an architecturally normal, physiological epithelium. Likewise the mechanisms of 339 
CIN are not well understood; our study paves the way for investigation of these CIN-340 
associated genes in model systems to elucidate their role. 341 
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We present here the first major whole genome sequencing data of pre-invasive lung 342 
lesions. We acknowledge that, despite using the world’s largest cohort of such lesions, the 343 
study remains underpowered to detect less common genomic alterations. Expanding our 344 
knowledge in this area will require a major international collaboration. Likewise we 345 
acknowledge that whilst our predictive signatures demonstrate the power of molecular data 346 
in guiding management decisions, a prospective clinical trial using predictors derived from 347 
our data will be required before clinical use. Again, international collaboration will be 348 
required to develop an appropriately powered trial. 349 
Despite these limitations, our data offer the first insight into the molecular map of 350 
early lung squamous cancer pathogenesis, foretelling an era in which molecular profiling will 351 
enable personally tailored therapeutic decisions for patients with pre-invasive lung disease. 352 
 353 
 354 
  355 
15 
 
Acknowledgements 356 
We thank all the patients who participated in this study and Kerra Pearce, George 357 
Chennel, David Chambers, Paul Mercer and Kate Gowers for technical help and proof 358 
reading. We thank Pamella Rabbitts, Anindo Banerjee and Cathy Read for their early 359 
development of the study. The results published here are in part based on data generated 360 
by a TCGA pilot project established by the National Cancer Institute and National Human 361 
Genome Research Institute. Information about TCGA and the investigators and institutions 362 
that constitute the TCGA research network can be found at http://cancergenome.nih.gov.  363 
Grants support: S.M.J. and P.J.C. are Wellcome Trust Senior Fellows in Clinical 364 
Science. S.M.J. is also supported by the Rosetrees Trust, the Welton Trust, the Garfield 365 
Weston Trust , the Stoneygate Trust and UCLH Charitable Foundation. V.T., C.P., R.E.H. 366 
and S.M.J. have been funded by the Roy Castle Lung Cancer Foundation. A.P. is funded by 367 
a Wellcome Trust clinical PhD training fellowship. H.L.-S. is funded by the Wellcome Trust 368 
Sanger Institute non-clinical PhD studentship. C.T. was a CRUK Clinician Scientist. This 369 
work was partially undertaken at UCLH/UCL who received a proportion of funding from the 370 
Department of Health’s NIHR Biomedical Research Centre’s funding scheme (S.M.J. and 371 
N.N.). S.M.J. and C.S. are part of the CRUK Lung Cancer Centre of Excellence. A.S., C.S. 372 
and S.M.J. are supported by Stand Up to Cancer. The funders had no role in study design, 373 
data collection and analysis, decision to publish or preparation of the manuscript.  374 
 375 
 376 
Author Contributions 377 
V.H.T, C.P.P. and A.P. contributed equally to this work. S.M.J., P.J.C., V.H.T., A.P., 378 
R.E.H., H.L.-S. and C.P.P. co-wrote the manuscript. S.M.J., P.J.C., C.T., V.H.T., and C.P.P. 379 
conceived the study design. S.M.J., P.J.C., C.T., V.H.T., C.P.P. and A.P. designed the study 380 
protocols. V.H.T. performed gene expression, qPCR and LCM experiments, analysed and 381 
integrated clinicopathological data and gene expression data. C.P.P. performed methylation 382 
and LCM experiments, analysed and integrated clinicopathological data and methylation 383 
16 
 
data. A.P. analysed and integrated clinicopathological data, WGS data, gene expression 384 
data and methylation data. H.L.-S., A.G.L. and H.F. analysed WGS data. D.C. and P.N. 385 
performed LCM experiments. J.B. analysed gene expression data. T.J.M., A.K., A.F., C.E.B. 386 
and D.S.P. analysed methylation data. M.F. and A.C. conducted the pathological review. 387 
P.J.G., B.C., N.N., G.H., J.M.B. and R.M.T. performed bronchoscopies and collected the CIS 388 
and control biopsies. P.F.D. performed histological experiments. R.E.H., R.C.C., N.M., C.S., 389 
S.B. and A.S. gave advice and reviewed the manuscript. S.M.J. provided overall study 390 
oversight. 391 
 392 
Competing Interests Statement 393 
The authors declare the following competing interests: 394 
A.S. is an employee of Johnson and Johnson. Discoveries within this manuscript 395 
have led S.M.J. to lead on Patent Applications 1819453.0 and 1819452.2 filed with the UK 396 
Intellectual Property Office through UCL Business PLC. 397 
. 398 
 399 
 400 
 401 
 402 
  403 
17 
 
References 404 
1 Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer 405 
J Clin 55, 74-108 (2005). 406 
2 Torre, L. A., Siegel, R. L. & Jemal, A. Lung Cancer Statistics. Advances in experimental 407 
medicine and biology 893, 1-19, doi:10.1007/978-3-319-24223-1_1 (2016). 408 
3 Nicholson, A. G. et al. Reproducibility of the WHO/IASLC grading system for pre-409 
invasive squamous lesions of the bronchus: a study of inter-observer and intra-410 
observer variation. Histopathology 38, 202-208 (2001). 411 
4 van der Heijden, E. H., Hoefsloot, W., van Hees, H. W. & Schuurbiers, O. C. High 412 
definition bronchoscopy: a randomized exploratory study of diagnostic value 413 
compared to standard white light bronchoscopy and autofluorescence 414 
bronchoscopy. Respir Res 16, 33, doi:10.1186/s12931-015-0193-7 (2015). 415 
5 Thakrar, R. M., Pennycuick, A., Borg, E. & Janes, S. M. Preinvasive disease of the 416 
airway. Cancer Treat Rev 58, 77-90, doi:10.1016/j.ctrv.2017.05.009 (2017). 417 
6 Pipinikas, C. P. et al. Cell migration leads to spatially distinct but clonally related 418 
airway cancer precursors. Thorax 69, 548-557, doi:10.1136/thoraxjnl-2013-204198 419 
(2014). 420 
7 Jeremy George, P. et al. Surveillance for the detection of early lung cancer in patients 421 
with bronchial dysplasia. Thorax 62, 43-50, doi:10.1136/thx.2005.052191 (2007). 422 
8 Futreal, P. A. et al. A census of human cancer genes. Nat Rev Cancer 4, 177-183, 423 
doi:10.1038/nrc1299 (2004). 424 
9 Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 425 
500, 415-421, doi:10.1038/nature12477 (2013). 426 
10 Alexandrov, L. B. & Stratton, M. R. Mutational signatures: the patterns of somatic 427 
mutations hidden in cancer genomes. Current opinion in genetics & development 24, 428 
52-60, doi:10.1016/j.gde.2013.11.014 (2014). 429 
11 Cancer Genome Atlas Research, N. Comprehensive genomic characterization of 430 
squamous cell lung cancers. Nature 489, 519-525, doi:10.1038/nature11404 (2012). 431 
12 Jiang, F., Yin, Z., Caraway, N. P., Li, R. & Katz, R. L. Genomic profiles in stage I primary 432 
non small cell lung cancer using comparative genomic hybridization analysis of cDNA 433 
microarrays. Neoplasia 6, 623-635, doi:10.1593/neo.04142 (2004). 434 
13 Chujo, M. et al. Comparative genomic hybridization analysis detected frequent 435 
overrepresentation of chromosome 3q in squamous cell carcinoma of the lung. Lung 436 
Cancer 38, 23-29 (2002). 437 
14 Tonon, G. et al. High-resolution genomic profiles of human lung cancer. Proceedings 438 
of the National Academy of Sciences of the United States of America 102, 9625-9630, 439 
doi:10.1073/pnas.0504126102 (2005). 440 
15 Petersen, I. et al. Patterns of chromosomal imbalances in adenocarcinoma and 441 
squamous cell carcinoma of the lung. Cancer Res 57, 2331-2335 (1997). 442 
16 Balsara, B. R. & Testa, J. R. Chromosomal imbalances in human lung cancer. 443 
Oncogene 21, 6877-6883, doi:10.1038/sj.onc.1205836 (2002). 444 
17 Massion, P. P. et al. Genomic copy number analysis of non-small cell lung cancer 445 
using array comparative genomic hybridization: implications of the 446 
phosphatidylinositol 3-kinase pathway. Cancer Res 62, 3636-3640 (2002). 447 
18 Ried, T. et al. Mapping of multiple DNA gains and losses in primary small cell lung 448 
carcinomas by comparative genomic hybridization. Cancer Res 54, 1801-1806 (1994). 449 
18 
 
19 Rodrigues, M. F., Esteves, C. M., Xavier, F. C. & Nunes, F. D. Methylation status of 450 
homeobox genes in common human cancers. Genomics 108, 185-193, 451 
doi:10.1016/j.ygeno.2016.11.001 (2016). 452 
20 Matsubara, D. et al. Inactivating mutations and hypermethylation of the NKX2-453 
1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas. Cancer Sci 454 
108, 1888-1896, doi:10.1111/cas.13313 (2017). 455 
21 Winslow, M. M. et al. Suppression of lung adenocarcinoma progression by Nkx2-1. 456 
Nature 473, 101-104, doi:10.1038/nature09881 (2011). 457 
22 Tata, P. R. et al. Developmental History Provides a Roadmap for the Emergence of 458 
Tumor Plasticity. Dev Cell 44, 679-693 e675, doi:10.1016/j.devcel.2018.02.024 459 
(2018). 460 
23 van Boerdonk, R. A. et al. DNA copy number aberrations in endobronchial lesions: a 461 
validated predictor for cancer. Thorax 69, 451-457, doi:10.1136/thoraxjnl-2013-462 
203821 (2014). 463 
24 Lee, K., Kim, J. H. & Kwon, H. The Actin-Related Protein BAF53 Is Essential for 464 
Chromosomal Subdomain Integrity. Mol Cells 38, 789-795, 465 
doi:10.14348/molcells.2015.0109 (2015). 466 
25 Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of 467 
chromosomal instability inferred from gene expression profiles predicts clinical 468 
outcome in multiple human cancers. Nat Genet 38, 1043-1048, doi:10.1038/ng1861 469 
(2006). 470 
26 Luo, W., Friedman, M. S., Shedden, K., Hankenson, K. D. & Woolf, P. J. GAGE: 471 
generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 472 
10, 161, doi:10.1186/1471-2105-10-161 (2009). 473 
27 Endesfelder, D. et al. Chromosomal instability selects gene copy-number variants 474 
encoding core regulators of proliferation in ER+ breast cancer. Cancer Res 74, 4853-475 
4863, doi:10.1158/0008-5472.CAN-13-2664 (2014). 476 
28 Blackburn, A. et al. Effects of copy number variable regions on local gene expression 477 
in white blood cells of Mexican Americans. Eur J Hum Genet 23, 1229-1235, 478 
doi:10.1038/ejhg.2014.280 (2015). 479 
29 Mileyko, Y., Joh, R. I. & Weitz, J. S. Small-scale copy number variation and large-scale 480 
changes in gene expression. Proceedings of the National Academy of Sciences of the 481 
United States of America 105, 16659-16664, doi:10.1073/pnas.0806239105 (2008). 482 
30 McGranahan, N., Burrell, R. A., Endesfelder, D., Novelli, M. R. & Swanton, C. Cancer 483 
chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 13, 528-484 
538, doi:10.1038/embor.2012.61 (2012). 485 
31 Jamal-Hanjani, M. et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl 486 
J Med 376, 2109-2121, doi:10.1056/NEJMoa1616288 (2017). 487 
 488 
  489 
19 
 
 490 
 491 
Figure Legends 492 
 493 
Figure 1. Analysis of pre-invasive lung carcinoma-in-situ (CIS) lesions.  494 
(a) Detection of bronchial pre-invasive CIS lesions by autofluorescence bronchoscopy. (b) 495 
Histological outcomes of bronchial pre-invasive lesions. (c) Overview of the study protocol. 496 
Patients with identified CIS lesions underwent repeat bronchoscopy and rebiopsy every 4 497 
months. Definitive cancer treatment was only performed if pathological evidence of 498 
progression to invasive cancer was detected. The ‘index biopsy’ profiled in this study refers 499 
to the biopsy immediately preceding progression to invasive cancer or regression to low-500 
grade dysplasia or normal epithelium. (d) Venn diagram of different -omics analyses 501 
performed on laser capture microdissection (LCM)-captured CIS lesions. Due to the small 502 
size of bronchial biopsies, not all analyses were performed on all samples 503 
 504 
Figure 2. Genomic aberrations in pre-invasive lung carcinoma-in-situ (CIS) lesions. 505 
Circos diagram comparing CIS genomic profiles with TCGA LUSC data. The outer histogram 506 
(A), shows mutation frequencies of all genes in TCGA data. The inner histogram (D) shows 507 
mutation frequencies in our CIS data. Profiles appear similar and no statistically significant 508 
differences were identified between the two datasets. Genes previously identified as 509 
potential drivers of lung cancer are labelled. Between the two histograms, average copy 510 
number changes are shown for TCGA data (B) and CIS data (C). Copy number gains are 511 
shown in red, losses in blue. Although differences between whole-genome and whole-512 
exome sequencing techniques makes these datasets difficult to compare, we observe many 513 
similar features between the two; for example, gains in 3q and 5p, which are well recognised 514 
features of squamous cell lung cancer. In the centre of the circos plot, 39 rings represent the 515 
copy number profiles of our 39 samples, illustrating the individual contribution of each 516 
sample to the average values presented (E).  517 
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 518 
Figure 3. Altered methylation and gene expression in lung carcinoma-in-situ (CIS) 519 
lesions. 520 
(a) Hierarchical clustering of 1335 significantly differentially expressed genes in progressive 521 
(n=17) and regressive (n=16) CIS lesions, based on a discovery set. Biological and clinical 522 
factors including age at diagnosis, gender, smoking history (pack years) and COPD status 523 
had no effect on CIS lesion gene expression profile (high expression = purple, low 524 
expression = orange). (b) Hierarchical clustering of the top 1000 significantly differentially 525 
methylated positions (DMPs) between progressive (n=36) and regressive (n=18) CIS lesions 526 
and controls (n=33). Biological and clinical factors including age at diagnosis, gender and 527 
smoking history (pack years) status had no effect on the methylation profile (hypomethylated 528 
DMPs = blue, hypermethylated DMPs = orange). (c) Principle component analysis of all 529 
profiled genes in progressive (n=27) and regressive (n=24) CIS lesions showing a clear 530 
distinction between progressive and regressive groups (p=0.0017). (d) Principle component 531 
analysis of all methylation data in progressive (n=36), regressive (n=18) and control (n=33) 532 
CIS lesions showing a clear distinction between progressive and regressive groups 533 
(p=6.8x10-25). P values were calculated using multivariate ANOVA. 534 
 535 
Figure 4. Carcinoma-in-situ (CIS) gene expression and methylation profiles are 536 
predictive of progression to cancer.  537 
(a) Probability plot based on a 291-gene signature for correct class prediction (discovery set 538 
- red circles indicate progressive lesions, green circles indicate regressive lesions). (b) 539 
Challenging the 291-gene signature on a CIS validation set. Area under the curve (AUC) is 1 540 
using Receiver Operating Characteristic (ROC) analysis. (c) Application of the 291-gene 541 
signature to TCGA LUSC data. Our signature classified TCGA LUSC vs TCGA controls 542 
samples with AUC of 0.81 (green circles indicate TCGA controls, orange circles indicate 543 
TCGA LUSC). (d) Distribution of methylation beta values across the genome in TCGA 544 
controls, CIS regressive and progressive and TCGA LUSC samples. Most probes are 545 
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regulated at 0 or 1 in normal tissue but this regulation is reduced in both regressive and 546 
progressive CIS and TCGA LUSC samples. (e) Methylation Heterogeneity Index, defined as 547 
counts of methylation probes with 0.26 < ß < 0.88, for each sample. MHI is higher in 548 
regressive and progressive CIS and TCGA LUSC compared with TCGA controls and this 549 
can be used as an accurate predictor with AUC=0.96 for TCGA LUSC vs TCGA controls and 550 
AUC=0.74 for progressive vs regressive CIS. (f) Histogram of AUC values calculated by 551 
performing the same analysis used in (e) 10,000 times, with each run limited to a different 552 
random sample of 2,000 probes (AUC mean for TCGA LUSC vs TCGA controls is 0.95 553 
(95% CI 0.92−0.98)). This demonstrates that a random sample of methylation probes can be 554 
an accurate predictor using this method. 555 
 556 
Figure 5. Chromosomal instability is associated with progression to cancer. 557 
(a) Mean expression of CIN-associated genes in CIS samples. Progressive (n=27) and 558 
regressive (n=24) CIS samples are well differentiated with AUC=0.96. Green circles indicate 559 
regressive CIS lesions; red circles indicate progressive CIS. (b) Plot of NEK2 expression 560 
across CIS samples demonstrates increasing expression with progression to cancer. 561 
Expression of this gene alone classifies progressive vs regressive CIS with AUC=0.93. (c) 562 
Pathway analysis of gene expression data between progressive (n=17) and regressive 563 
(n=16) CIS shows a strong chromosomal instability (CIN) signal, based on a discovery set. 564 
This signal remains strong when cell cycle genes are removed from the CIN70 signature. (d) 565 
Pathway analysis of methylation data demonstrating several cancer-related pathways up-566 
regulated in progressive CIS compared with regressive CIS. Quoted significance values in 567 
(c) and (d) are calculated using 2-sided t-tests adjusted for multiple testing using a False 568 
Discovery Rate method, as implemented in the GAGE Bioconductor package.  569 
  570 
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Tables 571 
 572 
  
W
hole 
genom
e 
sequencing 
set  (N
=39) 
M
ethylation 
discovery 
set (N
=60) 
M
ethylation 
validation 
set (N
=27) 
G
ene 
expression 
discovery 
set  (N
=33) 
G
ene 
expression 
validation 
set  (N
=18) 
Clinical 
Characteristics 
Progression 
R
egression 
Progression 
R
egression 
C
ontrols 
Progression 
R
egression 
C
ontrols 
Progression 
R
egression 
Progression 
R
egression 
Patients 21 8 13 7 16 9 7 8 16 14 9 8 
Lesions Profiled 29 10 26 11 23 10 7 10 17 16 10 8
Gender                         
Male 18 8 11 7 15 7 7 7 14 10 7 4 
Female 3 0 2 0 1 2 0 1 2 4 2 4
Age at 
bronchoscopy 
(years)                         
Mean 71.1 63.1 69.81 63.27 65.96 70.2 69.86 64.3 69.29 66.56 69.4 68.125 
Median 72 65.5 70 67 68 73 68 63 70 67.5 71.5 68 
Range 
58-
81 52-71 52-79 53-79 44-77 58-78 64-76 56-77 55-80 53-81 56-82 57-84 
Smoking 
History (pack 
years)           
Mean 54.4 54.9 58.08 31 41.95 57.3 62.14 37.71 57.07 47 49.125 59.2 
Median 50 50 59.5 29 40 60 50 36 50 47.5 47.5 58 
Range 
30-
100 9-141 32-141 5-88 20-65 40-75 30-141 20-60 22-141 5-141 30-75 30-96 
COPD status                         
Yes 12 3 9 3 14 5 1 7 4 8 3 7 
No 9 5 4 4 1 4 6 1 12 6 1 0 
Previous 
History of Lung 
Cancer           
Yes 12 2 6 2 9 7 4 3 5 4 3 4 
No 9 6 7 5 7 2 3 5 11 10 6 4 
 573 
Table 1. Demographic and clinical characteristics. 574 
Table showing demographic and clinical characteristics of patients in the whole-genome 575 
sequencing, methylation discovery and validation, and gene expression discovery and 576 
validation datasets. 577 
 578 
  579 
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Methods 580 
 581 
Ethical approval 582 
 All tissue and bronchial brushing samples were obtained under written informed 583 
patient consent and were fully anonymised. Study approval was provided by the UCL/UCLH 584 
Local Ethics Committee (REC references 06/Q0505/12 and 01/0148). All relevant ethical 585 
regulations were followed. 586 
 587 
Code availability 588 
 589 
All code used in our analysis will be made available at http://github.com/ucl-590 
respiratory/preinvasive on publication. All software dependencies, full version information, 591 
and parameters used in our analysis can be found here.  592 
 Unless otherwise specified, all analyses were performed in an R statistical 593 
environment (v3.5.0; www.r-project.org/) using Bioconductor1 version 3.7. 594 
 595 
Biological samples 596 
 All patients with pre-invasive lung cancer lesions were recruited through University 597 
College London Hospitals (UCLH) Early Lung Cancer Surveillance Programme (ELCSP). 598 
Full details of the surveillance protocol including eligibility criteria for patient inclusion have 599 
been previously described.2 Briefly, the programme has recruited 140 patients to date with 600 
pre-invasive lung cancer lesions of varying histological grades. Patients undergo 601 
autofluorescence bronchoscopy (AFB) and CT/PET scans every four to six months during 602 
which multiple biopsy specimens are collected. This longitudinal sequential AFB procedure 603 
provides biopsies of the same lesion sampled repeatedly over time, allowing us to monitor 604 
whether the individual lesions have progressed, regressed or remained static2.  605 
 For a given CIS lesion under surveillance, when a biopsy from the same site showed 606 
evidence of progression to invasive cancer or regression to normal epithelium or low-grade 607 
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dysplasia, we define the preceding CIS biopsy as the ‘index’ lesion. An index lesion was 608 
defined as progressive if the subsequent biopsy at the same site showed invasive cancer, or 609 
as regressive if the subsequent biopsy showed normal epithelium or low-grade disease 610 
(metaplasia, mild or moderate dysplasia). Lesions which do not satisfy one of these end-611 
points were excluded from this study. Patients with multiple fresh-frozen (FF) and formalin-612 
fixed, paraffin-embedded (FFPE) tissue biopsies were identified for DNA methylation and 613 
gene expression analysis, respectively. Laser-capture micro-dissection (LCM) was used to 614 
selectively isolate CIS cells for molecular analysis, reducing the extent of contamination by 615 
stromal cells.  616 
 The following protocol was used to determine which profiling methods were applied to 617 
a given CIS lesion during our initial data collection phase: 618 
• If FFPE samples were available, gene expression profiling was performed. For the first 619 
33 samples (17 progressive and 16 regressive), gene expression profiles were 620 
generated using Illumina microarrays. Our predictive models are trained on this 621 
discovery set. Subsequently, a further set of 10 progressive and 8 regressive 622 
samples from 18 patients were profiled using a different microarray platform 623 
(Affymetrix) to validate our findings on an independent platform. 624 
• If FF samples were available, DNA from these samples was first used for methylation 625 
profiling. Samples with sufficient DNA after DNA profiling were additionally subjected 626 
to whole-genome sequencing. After acquisition of sufficient samples for our 627 
methylation dataset (54 samples; 36 progressive, 18 regressive), only 29 samples 628 
had sufficient DNA for WGS, therefore we prioritised WGS over methylation for the 629 
subsequent 10 samples. 630 
 631 
Tissue processing and laser-capture micro-dissection 632 
 FF or FFPE tissue sections (7-10μM thickness) were mounted on a MembraneSlide 633 
1.0 PEN. Prior to cryosectioning, the slides were heat-treated for 4 h at 180°C in a drying 634 
cabinet to inactivate nucleases. To overcome the membrane’s hydrophobic nature and to 635 
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allow better section adherence, the slides were then UV-treated for 30 min at 254nm. Prior 636 
to laser-capture micro-dissection (LCM), the slides containing the FF tissue sections for DNA 637 
extraction were washed in serial ethanol dilutions (50, 75, 100%) to remove the freezing 638 
medium (OCT) and to avoid any interference with the laser’s efficiency. For RNA extraction, 639 
FFPE sections were dewaxed using the Arcturus® Paradise® PLUS Reagent System 640 
(Applied Biosystems, Foster City, CA, USA). For each case, epithelial areas of pre-invasive 641 
disease were identified by haematoxylin and eosin staining of the corresponding cryosection 642 
(~7 μM thick). The presence of epithelial areas of interest was confirmed by histological 643 
assessment of each case by two histopathologists. LCM to isolate the tissue area/cells of 644 
interest was performed with the PALM MicrobeamTM system (Carl Zeiss MicroImaging, 645 
Munich, Germany) on unstained sections. The micro-dissected material was catapulted into 646 
a 500μl AdhesiveCap that allows capture of the isolated tissue without applying any liquid 647 
into the cap prior to LCM, thus minimizing the risk of nuclease activity. The captured cells 648 
were stored at -80°C until DNA extraction or processed immediately for RNA.  649 
 650 
 651 
DNA extraction 652 
 DNA from the micro-dissected tissue and bronchial brushing samples was extracted 653 
using QIAGEN’s QIAmp DNA Mini and Micro kits, respectively (Crawley, UK). Soluble carrier 654 
RNA was used to increase tissue DNA yield. Concentration was measured using the Qubit® 655 
dsDNA High-Sensitivity assay and Qubit® 2.0 Fluorometer (Life Technologies, Paisley, UK). 656 
Nucleic acid quality and purity was estimated based on the A260/280 absorbance ratio 657 
readings using the NanoDrop-8000 UV-spectrophotometer (Thermo Scientific, Hertfordshire, 658 
UK). Only samples with an A260/280 ratio of 1.7-1.9 were included in the study. 659 
 660 
RNA extraction 661 
 RNA was extracted using the High Pure FFPE RNA Kit (Roche Applied Science, West 662 
Sussex, UK) according to manufacturer’s protocol. Quantification was carried out using the 663 
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Quant-iT RNA assay kit and the Qubit® 2.0 fluorometer (Life Technologies, Paisley, UK). 664 
RNA integrity was analyzed using a BioAnalyzer 2100 (Agilent, Stockport, UK). 665 
 666 
Bisulfite conversion 667 
 For each sample undergoing methylation profiling, 200 ng of DNA were bisulfite 668 
converted using the EZ DNA methylation kit (Zymo Research Corp., Orange, CA, USA) 669 
according to the manufacturer’s modified protocol for Illumina’s Infinium 450K assay. This 670 
protocol incorporates a cyclic denaturation step to improve the conversion efficiency3. The 671 
10 μl final conversion reaction was concentrated down to 4 μl with a vacufuge plus vacuum 672 
concentrator (Eppendorf AG, Hamburg, Germany) and sent to UCL’s Genomics Core 673 
Facility for hybridization on the 450K BeadArray according to Illumina’s Infinium HD protocol 674 
(Illumina Inc., San Diego, CA, USA) as previously described.4  675 
 676 
Infinium HumanMethylation450K raw data extraction and pre-processing 677 
 Illumina’s iScan fluorescent system was used to scan and image the arrays. DNA 678 
methylation data were extracted as raw intensity signals without any prior background 679 
subtraction or data normalization and were stored as IDAT files.  680 
CpG-specific methylation levels (β-values; continuous value ranging from 0 to 1) for 681 
each sample were calculated as the ratio of the fluorescent signal intensity of the methylated 682 
(M) and unmethylated (U) alleles according to the following formula: 683 
 684 
 685 
 686 
All subsequent raw β-value pre-processing, normalisation and down-stream analysis 687 
was performed using the Chip Analysis Methylation Pipeline (ChAMP) Bioconductor 688 
package with default settings.5  689 
β = intensity of methylated allele (M)
intensity of [unmethylated (U) + methylated (M) allele] +100
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Analysis of differentially variable positions (DVP) was performed using iEVORA6. Beta 690 
values from ChAMP were used as input to iEVORA following normalization and batch 691 
correction. 692 
 693 
Genome-wide gene expression array  694 
The extracted FFPE RNA used to generate the gene expression profiles on the 695 
discovery set was sent to UCL’s Genomics Core Facility for hybridization on the Human 696 
Whole-Genome DASL (cDNA-mediated Annealing, Selection, extension and Ligation) 697 
beadarrays according to Illumina’s protocol (Illumina Inc., San Diego, CA, USA).  698 
The extracted FFPE RNA used to generate the gene expression profiles on the 699 
validation set was sent to UK Bioinformatics Limited for hybridization on the Clariom™ D 700 
Transcriptome Human Pico Assay 2.0 according to Affymetrix’s protocol (Thermo Fisher 701 
Scientific Waltham, MA, USA).  702 
 703 
Principal Component Analysis (PCA) 704 
 In order to identify any potential factors of variability affecting sample/group 705 
segregation, we applied principal component analysis on all probes passing filters defined 706 
above (implemented in the prcomp method of the R stats package). Technical and biological 707 
variation was investigated for batch arrays, smoking (pack-years), age at initial diagnosis, 708 
gender and previous lung cancer history. The ability of these features to predict the first 709 
principal component was quantified using ANOVA analysis, implemented in the R aov 710 
method. p-values quoted are derived from this method. 711 
 712 
Gene expression analysis 713 
 Raw gene expression data were expressed as log2 ratios of fluorescence intensities of 714 
the experimental samples. Quantile normalization was applied to Illumina data, using 715 
Illumina GenomeStudio Gene Expression Module v1.0 software. For Affymetrix data, RMA 716 
normalization was applied as defined in the affy Bioconductor package. For analyses 717 
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utilizing both data sets, only genes represented on both arrays were included and ComBat7 718 
was used to adjust for batch effects. 719 
 Differential expression analysis was performed using the limma8 Bioconductor 720 
package. Raw p-values were adjusted by the Benjamini-Hochberg procedure to give a 721 
FDR.9 A significance threshold of FDR < 0.01 was used to select differentially expressed 722 
genes. Cluster analysis and visualization was performed using the pheatmap10 Bioconductor 723 
package.  724 
 725 
Real Time PCR Validation  726 
For microarray validation, total RNA from the 33 pre-invasive LUSC lesions 727 
undergoing Illumina gene expression profiling was reverse transcribed using qScriptTM 728 
cDNA Super-Mix (Quanta Biosciences, Lutterworth, UK) according to the manufacturer’s 729 
protocol. Real-time quantitative PCR was carried out in eight genes using the SYBR-green 730 
master mix (Applied BioSystems, Bleiswijk, Netherlands) in an Eppendorf real-time PCR 731 
Machine (Eppendorf, Stevenage, UK). Findings were validated using quantitative PCR 732 
(qPCR) for four up-regulated (GAGE5, GPNMB, MMP12 and STC2) and four down-733 
regulated (SPDEF, LMO7, OBSCN and MT1E) genes. Gene-specific primers were designed 734 
inside or nearby the microarray sequence targeted, using Primer Express Software v2.0 735 
(Thermo Fisher Scientific). Relative gene expression was quantified using the threshold 736 
cycle (Ct) method and normalized to the amount of CTBL and CEP250, which met the 737 
criteria of less variation between samples and compatible expression level with the studied 738 
genes. Each sample was tested in triplicate and a sample without template was included in 739 
each run as a negative control. Correlations between microarrays and real time PCR data 740 
were measured using the Pearson coefficient. From microarray and real time PCR data, we 741 
calculated the progressive/regressive ratio for each gene expression. All eight genes tested 742 
were significant in our differential microarray analysis with FDR < 0.05. A high degree of 743 
correlation (r=0.982) was observed between qPCR and array data. 744 
 745 
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Predictive modelling 746 
 For methylation, gene expression and copy number data we applied Prediction 747 
Analysis of Microarrays (PAM)11 to predict whether a sample was progressive or regressive 748 
based on its molecular profile. The Bioconductor pamr package was used. In all presented 749 
analyses we select a threshold which minimizes the number of data inputs required whilst 750 
maintaining the minimum possible number of classification errors. 751 
 PAM calculates the probability of each sample being progressive. We describe this 752 
value as a ‘Progression Score’. ROC analytics were performed on these progression scores 753 
to determine their value as a diagnostic test, using the pROC12 and PRROC13 Bioconductor 754 
packages. 755 
 For methylation and gene expression data a predictive model was trained on the 756 
training set and subsequently applied to an independent validation set. Regressive and 757 
control samples were grouped together for the methylation data analysis. ROC analytics 758 
were performed only on the validation set. Internal cross-validation was used for 759 
methylation-derived copy number data due to smaller sample size (control samples are used 760 
as a baseline to calculate copy number, therefore are excluded from predictive analysis).   761 
 When multiple lesions from one patient were included in an analysis, these were 762 
treated as independent events as they were always taken from different sites in the lung. 763 
The outcome of a lesion (whether it progressed or regressed) was determined on a per-764 
lesion basis; the lesion was assigned to the progressive group only if cancer developed at 765 
the same site in the lung, and to the regressive group only if normal or low-grade dysplasia 766 
was obtained from the same site in the lung. 767 
 In some cases different technologies were used, for example our gene expression 768 
discovery set used Illumina microarrays whereas our validation set used Affymetrix. In such 769 
instances, both data sets were reduced to the subset of genes covered by probes in both 770 
platforms prior to creating a predictive model. The ComBat method from the sva 771 
Bioconductor package was used to correct for batch effects between the different platforms. 772 
In the case of RNAseq data, we used the voom transformation defined in the limma 773 
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Bioconductor package to derive data comparable to expression data prior to batch correction 774 
with ComBat. 775 
 A second predictive model based on methylation probe variation was also developed. 776 
For a given sample we defined Methylation Heterogeneity Index (MHI) by counting all 777 
probes with beta values between 0.26 and 0.88. These thresholds were optimized by 778 
calculating MHI for a range of different threshold values, and choosing those with the highest 779 
AUC for progressive vs regressive in our discovery cohort. We used ROC analytics to 780 
assess this model as a predictor of TCGA cancer vs control samples, and of progressive vs 781 
regressive samples in our validation cohort. We demonstrate in the main text that applying 782 
this method to a random sample of 2,000 probes performs similarly to using the entire array. 783 
We ran simulations using different sample sizes and found that performance with n=2000 784 
was similar to that of the entire array. To investigate potential confounding variables we use 785 
binomial logistic regression, implemented in the R glm method, to assess whether outcome 786 
(progression/regression) could be predicted by MHI, smoking status, COPD, previous history 787 
of lung cancer, age or gender. Control samples derived from brushings were excluded from 788 
these analyses. 789 
 790 
Copy number variation analysis 791 
 For samples with whole-genome sequencing available we used ASCAT14 to derive 792 
local copy number estimates as described below. To increase our sample size for 793 
comparative analyses, Copy number variation (CNV) data were obtained from non-794 
normalised methylated and unmethylated signal intensities of probes in the 450K array as 795 
previously described15 using the ChAMP Bioconductor package with default settings. Copy 796 
number (CN) profiles for progressive and regressive cases were obtained using the control 797 
cases for baseline normalisation. A previously defined threshold of ±0.3 was used for the 798 
identification of single CNV. Probes associated with highly polymorphic regions (e.g. major 799 
histocompatibility complex) were removed from the analysis. The analysis generated group 800 
CN frequency plots and CN profiles for each sample. For samples with both methylation and 801 
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sequencing data available we observed good correlation between copy numbers derived 802 
from the two different methods (data not shown). 803 
 For comparison with previous results, the ChAMP pipeline was then modified to return 804 
CNV values per-probe. Probe locations were matched to cytogenetic bands using the 805 
Ensembl GRCh37 assembly, obtained from 806 
http://grch37.rest.ensembl.org/info/assembly/homo_sapiens?content-807 
type=application/json&bands=1, such that copy number variation could be assessed by 808 
cytogenetic band. The mean CNV value for each of 778 cytogenetic bands was calculated 809 
for each of our 54 samples. Limma analysis was used to identify bands that differed 810 
significantly between progressive and regressive samples with BH-adjusted p-value < 0.05. 811 
Predictive modelling was performed using PAM to find bands predictive of progression, 812 
using the same method as for gene expression data. Due to the low number of regressive 813 
samples, an internal cross-validation method was used rather than separate discovery and 814 
validation sets. 815 
 Following identification of predictive cytogenetic bands, PAM modelling was repeated 816 
with the dataset limited to only those bands identified by van Boerdonk et al: 3q26.2−29, 817 
3p26.3−p11.1 and 6p25.3−p24.3.16,17 This model was also accurate. 818 
 Finally, we applied our model to the validation data set of 24 regressive and 12 819 
progressive samples used by van Boerdonk et al (GEO accession number GSE45287). 820 
These data were measured using a different microarray platform (arrayCGH). We assigned 821 
each probe to a cytogenetic band, and took the mean values to create a matrix of 822 
expression values by band. Our model was applied to the subset of chromosomal bands 823 
present in both data sets (760 of 778 bands). ComBat was used for batch correction 824 
between the two platforms. Our model correctly predicted 24/24 regressive samples and 825 
9/12 progressive samples, replicating the results of van Boerdonk et al. 826 
 827 
External validation using TCGA 828 
 Lung cancer methylation datasets publically available through The Cancer Genome 829 
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Atlas (TCGA) were downloaded using GenomicDataCommons download tools18. We 830 
obtained the normalized β-values of 370 LUSC samples and 42 normal controls. ComBat 831 
was used to correct for batch effects between our data and TCGA data. These data were 832 
used as an external validation set to test our predictive models, and as input for our 833 
differential analysis of progression drivers from control through CIS to cancer. 834 
 Gene-expression microarray data sets comparable to our data were not publically 835 
available. RNAseq data was available from TCGA for 502 LUSC samples and 49 control 836 
samples. We applied a voom transformation19 to these data, which uses normalized log-837 
counts-per-million as an approximation for expression values, and hence allows comparison 838 
of RNAseq data with our gene expression pipeline. ComBat was used to correct for batch 839 
effects. The predictive model generated using PAM on our gene expression microarray data 840 
was applied to voom-transformed RNAseq data from TCGA and shown to be predictive (Fig. 841 
4C). We therefore demonstrate the applicability of our model to this fully independent data 842 
set. These data were again used as input to our differential analysis of progression drivers. 843 
 844 
Pathway analysis 845 
 For gene expression data, the GAGE Bioconductor package20 was used with KEGG 846 
gene sets21-23 to identify pathways associated with genes differentially expressed in our 847 
analysis of progression to cancer (BH-adjusted p-value <0.01). In addition to these pathways 848 
we use the CIN70 signature defined by Carter et al.24 to assess for a chromosomal instability 849 
signal. We also use a subset of the CIN70 genes with cell-cycle associated genes25 850 
removed to ensure that our signal is genuinely CIN-related, rather than a measure of 851 
proliferation. 852 
 Methylation data was analysed in the same way, using beta values as input to GAGE. 853 
In cases where there are multiple methylation probes for a single gene we use the mean 854 
beta value over that gene as input to pathway analysis. We acknowledge that using mean 855 
signal may be insensitive to single-probe methylation changes, however given the scale of 856 
changes observed we believe it will identify areas of large methylation change. 857 
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 858 
Genomic sequencing 859 
We created genome-wide shotgun libraries (insert size 331-367 bp) from native DNA 860 
using the Agilent Technologies Custom SureSelect Library Prep Kit library (cat no. 930075). 861 
150 bp paired-end sequence data were generated using the Illumina HiSeq X Ten system. 862 
Sequenced data were realigned to the human genome (NCBI build 37) using BWA-MEM. 863 
Unmapped reads and PCR duplicates were removed. A minimum sequencing depth of 40x 864 
was required. 865 
 866 
Somatic mutation calling and annotation 867 
Single base somatic substitutions were identified by our in-house algorithm Cancer 868 
Variants through Expectation Maximisation (CaVEMan: 869 
https://github.com/cancerit/CaVEMan)26. This algorithm compares the sequence data from 870 
each tumour sample to its matched normal and calculates a mutation probability at each 871 
locus. This calculation incorporates information from aberrant cell fraction and copy number 872 
estimates from the Allele-Specific Copy number Analysis of Tumours (ASCAT) algorithm 873 
(https://www.crick.ac.uk/peter-van-loo/software/ASCAT).14,27 Additional post-processing as 874 
described previously28 was implemented. Any putative driver mutations were visually 875 
inspected with Jbrowse.29 For every substitution that passed all filters in at least one sample, 876 
we counted the number of wild-type and mutant reads at the same position in all other 877 
samples from the same patient to see if that mutation was also present in related samples 878 
but had not been called.  879 
 880 
Somatic small insertions and deletions 881 
These were identified using our in-house algorithm Pindel.30,31 As with substitutions, all 882 
putative driver mutations were visualised with Jbrowse. 883 
 884 
Somatic structural variant detection” 885 
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Abnormally paired read pairs were grouped using an in-house tool, “Brass”.32 Read 886 
groups overlapping genomic repeats, reads from the matched normal, or from a panel of 887 
unmatched normals were ignored. Read pair clusters were then filtered by read remapping. 888 
Read pair clusters with >50% of the reads mapping to microbial sequences were removed. 889 
Finally, candidate SV breakpoints were matched to copy number breakpoints as defined by 890 
ASCAT within 10 kb. Candidate SVs that were not associated with copy number 891 
segmentation breakpoints and with a copy number change of at least 0.3 were removed.  All 892 
putative driver rearrangements were visually inspected using IGV.33,34 893 
 894 
Somatic copy number events, ploidy, and stromal contamination 895 
Copy number changes were derived from whole-genome sequencing data using the 896 
ASCAT algorithm. This algorithm compares the relative representation of heterozygous 897 
SNPs and the total read depth at these positions to estimate the aberrant cell fraction and 898 
ploidy for each sample, and then to determine allele-specific copy number.  899 
 900 
Weighted Genome Integrity Index 901 
 To estimate the overall chromosomal instability of a sample, we use the Weighted 902 
Genome Integrity Index (wGII) score35. This is calculated by measuring the percentage of 903 
the genome which is abnormal, corrected such that each chromosome is equally weighted.  904 
 905 
Mutation annotation 906 
Lung cancer driver genes were selected from the COSMIC Cancer Gene Census 907 
(CGC) v85 (cancer.sanger.ac.uk)36. CGC data was downloaded on 20th June 2018. Genes 908 
annotated in the CGC as potential drivers in lung cancer or NSCLC were included. Those 909 
specific to adenocarcinoma were excluded as our samples are precursors to squamous 910 
cancers. Genes identified in two large studies of squamous cell cancer, and some additional 911 
genes based on expert curation of the literature (ARID1A, AKT2, FAT1, PTPRB) were 912 
included if they were present in the CGC – even if they were not annotated explicitly as 913 
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implicated in lung cancer. Both Tier 1 and Tier 2 genes were included. A total of 96 genes 914 
were selected as putative lung squamous cell carcinoma drivers (Supplementary Table 4). 915 
 Mutations affecting these putative driver genes were annotated as driver mutations if 916 
they passed the following filters: 917 
• The mutation type (e.g. missense, frameshift, amplification) must have been validated 918 
in the CGC for the affected gene. 919 
• For genes annotated as tumour suppressors, mutations determined to have High or 920 
Moderate impact using Ensembl’s Variant Effect Predictor37 were classed as driver 921 
mutations. 922 
• For genes annotated as oncogenes, we checked the specific mutation against 923 
COSMIC mutation data for lung carcinomas. If the specific mutation occurred 3 or 924 
more times in this dataset it was classed as a driver mutation. 925 
• For genes annotated as fusion proteins, translocations with a translocation partner 926 
gene matching validated tranlocation partner genes in the CGC were classed as 927 
driver events. 928 
• Copy number amplifications and deletions were all classed as driver events if 929 
amplifications/deletions in the affected gene have been previously validated in the 930 
CGC. We included homozygous deletions of tumour suppressor genes and 931 
amplifications to more than double the sample ploidy for oncogenes. 932 
 933 
 Driver mutation discovery was also attempted using dndscv38. This was 934 
underpowered, however, and only yielded TP53 and CDKN2A as genes under positive 935 
selection. This package was also used to estimate the global dNdS for both progressive and 936 
regressive lesions. 937 
 938 
Subclonality analysis 939 
The number of subclones contributing to a sample and their relative contribution was 940 
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estimated by using a modified version of the sciClone Bioconductor package39. sciClone 941 
uses a Bayesian method to allocate mutations to clusters based on their variant allele 942 
frequency (VAF). By default, sciClone only considers regions that are copy number neutral 943 
and LOH-free. Given the significant aneuploidy in our data set we overcame this limitation by 944 
clustering on cancer cell fraction (CCF) rather than VAF. Briefly, cancer cell fraction 945 
represents the fraction of cancer cells in which a given mutation is present, therefore clonal 946 
mutations will have CCF=1. Following the method of McGranahan et al.40, we estimated the 947 
CCF for each mutation with a 95% confidence interval. Mutations for which 1 lay within this 948 
confidence interval were labelled as ‘clonal’, other mutations as ‘subclonal’. 949 
CCF values for each mutation were then used as input to sciClone in place of VAF 950 
values to quantify clusters present (divided by 2 such that clonal mutations have a value of 951 
0.5). As CCF corrects for local copy number, all regions were assumed to have copy number 952 
of 2, allowing sciClone to group mutations based only on their CCF estimates. A minimum 953 
tumour sequencing depth of 10 was required for each mutation. 954 
 Where more than one sample from a given patient was available, both one 955 
dimensional and multi-dimensional clustering were performed. Results from one dimensional 956 
clustering were used in the comparison of numbers of clones and proportion of clonal 957 
mutations between progressive and regressive lesions, in order to provide as fair a 958 
comparison as possible. 959 
 960 
Extraction of mutational signatures  961 
To obtain an approximate estimate of the contribution of different known mutational 962 
signatures to each sample, we used the MutationalPatterns Bioconductor package41. As a 963 
reference set of mutational signatures, we used a table with the relative frequency of each of 964 
the 96 trinucleotide substitutions across 30 known mutation signatures,42,43 available through 965 
the COSMIC website (http://cancer.sanger.ac.uk/cosmic/signatures). 966 
 After a first run which indicated the most likely contribution of each signature, it 967 
seemed that the majority of substitutions were contributed by signatures 1, 2, 4, 5, and 13, 968 
37 
 
which have been described to be the strongest signatures in lung squamous cell cancer.44 969 
Some contribution was identified from signatures 16, 8, 18 and 3 in our initial analysis; 970 
however, in this context it is likely that these represent overfitting given that signature 16 is 971 
similar to signature 5, and signatures 8, 18 and 3 are similar to signature 4. We therefore ran 972 
the algorithm a second time, this time only using a 5x96 matrix of mutational signatures 1, 2, 973 
4, 5 and 13. All mutations were thus forced to belong to one of these five mutational 974 
signatures. 975 
 For a comparison of the clonal vs subclonal mutational processes in each sample, 976 
substitutions were annotated as clonal or subclonal based on CCF as described above. 977 
These were then run through the MutationalPatterns package. 978 
 979 
Comparison of mutational burden and signatures with other cancer types 980 
Signatures of mutations in our CIS dataset were compared with mutational signatures 981 
found in lung squamous cell cancer.  Raw whole-exome sequencing data for this cancer 982 
type was downloaded from TCGA, and run through our substitution-calling algorithm 983 
CAVEMaN as described above. We then looked at the total number of subsitutions called, 984 
and estimated the contribution of each mutational signature using the methods described 985 
above. Only coding regions of the CIS whole-genome sequencing data were compared to 986 
these exomes. 987 
 988 
Estimation of telomere lengths 989 
Telomere lengths were estimated using telomerecat45, and were compared in 990 
progressive and regressive groups. Telomerecat is a de novo method for the estimation of 991 
telomere length (TL) from whole-genome sequencing samples. The algorithm works by 992 
comparing the ratio of full telomere reads to reads on the boundary between telomere and 993 
subtelomere. This ratio is transformed to a measure of length by taking into account the 994 
fragment length distribution. Telomerecat also corrects for error in sequencing reads by 995 
modeling the observed distribution of phred scores associated with mismatches in the 996 
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telomere sequence. Samples were analysed in two groups corresponding to two separate 997 
sequencing batches, as per the telomerecat documentation. 998 
 999 
Data Availability Statement 1000 
 Whole-genome sequencing data have been deposited at the European Genome 1001 
Phenome Archive (https://www.ebi.ac.uk/ega/ at the EBI) with accession number 1002 
EGAD00001003883. All gene expression and methylation microarray data reported in this 1003 
study have been deposited in the National Center for Biotechnology Information Gene 1004 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) public repository, and they 1005 
are accessible through GEO accession number GSE108124. 1006 
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